Small molecule inhibitor shows promise in trastuzumab-resistant metastatic breast cancer

ORLANDO (June 1, 2009)?Fox Chase Cancer Center researchers report that a combination of trastuzumab and neratinib (HKI-272) a novel small molecule inhibitor of the HER2 receptor (ErbB2) appears active in women with HER2-positive metastatic breast cancer who have progressed on previous trastuzumab based therapies.

Read the whole article on Science Blog

More from Science Blog